Key Insights

Highlights

No notable highlights available yet

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 40/100

Termination Rate

0.0%

0 terminated out of 7 trials

Late-Stage Pipeline

14%

1 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed with results

Key Signals

Data Visualizations

Phase Distribution

2Total
Not Applicable (1)
P 3 (1)

Trial Status

Recruiting4
Unknown2
Active Not Recruiting1

Clinical Trials (7)

Showing 7 of 7 trials
NCT07491016RecruitingPrimary

Efficacy and Safety of Telitacicept Combined With Baricitinib for Refractory Rheumatoid Arthritis

NCT07053137Active Not Recruiting

A Comparative Study of the Efficacy and Safety of Telitacicept and Belimumab in the Treatment of Systemic Lupus Erythematosus Involving Multiple Units, Based on Previous Data.

NCT06979271RecruitingPrimary

Efficacy and Safety of Telitacicept Combined With Tofacitinib for Refractory Rheumatoid Arthritis

NCT06654596Not ApplicableRecruiting

Efficacy and Safety of Telitacicept in IgAN

NCT06125405Phase 3Recruiting

Study of the Telitacicept in Pediatric Patients With Frequently Relapsing or Steroid Dependent Nephrotic Syndrome

NCT06137053UnknownPrimary

Effect of Telitacicept on Transitional Regulatory B Cells in Patients With Systemic Lupus Erythematosus

NCT05588830Unknown

The Efficacy and Safety of Telitacicept and Belimumab in Active Lupus Nephritis in the Real World: a Prospective Cohort Study

Showing all 7 trials

Research Network

Activity Timeline